8-K: Trevi Therapeutics Reports Q3 2025 Results, Advances Haduvio

Trevi Therapeutics announced its third quarter 2025 financial results and provided updates on its Haduvio clinical programs, including plans for a Phase 3 initiation in early 2026.

Summary

• Reported financial results for the quarter ended September 30, 2025.
• Ended Q3 2025 with $194.9 million in cash, cash equivalents, and marketable securities.
• Expected cash runway extends into 2028.
• Preparing to initiate a comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) in the first half of 2026.
• On track to submit an End-of-Phase 2 meeting request to the FDA in Q4 2025 for the IPF chronic cough program.
• Completed a Phase 1 drug-drug interaction study showing no clinically meaningful pharmacokinetic findings for Haduvio when co-administered with standard antifibrotic therapies.
• Planning to initiate a Phase 2b study for refractory chronic cough (RCC) in the first half of 2026, following positive Phase 2a RIVER trial results.
• Net loss for Q3 2025 was $11.8 million, an improvement from $13.2 million in Q3 2024.

Sentiment

Score: 8

Explanation: The company reported improved financial metrics with a reduced net loss and significantly increased cash reserves, extending its runway. Strong progress in clinical trials for Haduvio, including successful completion of a Phase 1 DDI study and plans for Phase 3 and Phase 2b initiations, indicates positive momentum in addressing high unmet medical needs.

Positives

• Strong cash position of $194.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Extended cash runway into 2028, providing significant financial stability for ongoing development.
• Net loss decreased to $11.8 million in Q3 2025 from $13.2 million in Q3 2024.
• Basic and diluted net loss per common share improved to $(0.08) in Q3 2025 from $(0.13) in Q3 2024.
• Successful completion of a Phase 1 drug-drug interaction study with no clinically meaningful pharmacokinetic findings for Haduvio with standard antifibrotic therapies.
• Safety review committee for the Phase 1 TIDAL study found no safety signals and approved full enrollment.
• Advancement towards a comprehensive Phase 3 program for IPF chronic cough in H1 2026 and a Phase 2b RCC study in H1 2026.
• Increased other income, net, to $2.1 million in Q3 2025 from $0.8 million in Q3 2024, primarily due to higher interest income.

Negatives

• Continued net loss of $11.8 million for the third quarter of 2025.
• General and administrative (G&A) expenses increased to $3.8 million in Q3 2025 from $2.9 million in Q3 2024, primarily due to professional fees and personnel-related expenses.
• Weighted average common shares used in net loss per share increased significantly to 145,104,986 in Q3 2025 from 101,282,228 in Q3 2024, indicating dilution.

Risks

• Uncertainties regarding the success, cost, and timing of product candidate development activities and clinical trials.
• The risk that positive data from a clinical trial may not necessarily be predictive of the results of later clinical trials in the same or a different indication.
• Uncertainties regarding the company's ability to execute on its strategy.
• Uncertainties with respect to regulatory authorities' views as to the data from clinical trials and next steps in the development path for Haduvio in the United States and foreign countries.
• Uncertainties inherent in estimating cash runway, future expenses, and other financial results, including the ability to fund future operations and clinical trials.

Future Outlook

The company plans to submit an End-of-Phase 2 meeting request to the FDA in the fourth quarter of 2025 for its IPF chronic cough program and aims to initiate a comprehensive Phase 3 program in the first half of 2026. Additionally, a Phase 2b study for refractory chronic cough is slated to begin in the first half of 2026. The company expects its current cash, cash equivalents, and marketable securities to fund operations into 2028.

Management Comments

• "Following positive clinical data for both IPF chronic cough and RCC earlier this year, our strong progress continues."
• "We have been executing on the studies necessary to advance our IPF chronic cough program and are on track to submit our End-of-Phase 2 meeting request to the FDA in the fourth quarter."
• "Our overall corporate strategy is built on a clear path for growth, focused on specialty indications in chronic cough that currently have no approved therapies in the U.S. and have significant negative impacts on the quality of life of the patients with these conditions."

Industry Context

Trevi Therapeutics operates in the biopharmaceutical sector, focusing on developing therapies for chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). These conditions represent areas of high unmet medical need, as there are currently no FDA-approved therapies in the U.S. for these specific indications. The company's investigational therapy, Haduvio, targets opioid receptors involved in the cough reflex, offering a novel mechanism of action in a market segment characterized by significant patient suffering and lack of effective treatments.

Comparison to Industry Standards

• Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials across both patients with IPF chronic cough and in patients with RCC.
• Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies in the U.S.
• Refractory chronic cough (RCC) is also a condition with high unmet need and no FDA-approved therapies in the U.S.
• The company's focus on specialty indications with no approved therapies positions it to potentially address significant market gaps, unlike companies developing therapies for conditions with existing treatment options.

Stakeholder Impact

• Shareholders: Potential positive impact due to extended cash runway, reduced net loss, and advancement of clinical programs, which could lead to future value creation if trials are successful. Dilution from increased share count is a consideration.
• Patients: Potential positive impact as Haduvio progresses towards approval for chronic cough in IPF, non-IPF ILD, and RCC, addressing significant unmet medical needs with no currently approved therapies.
• Employees: Continued employment and potential growth opportunities as clinical programs advance.
• Regulatory Authorities: Engagement with the FDA for End-of-Phase 2 meeting and future regulatory submissions.

Next Steps

• Submit End-of-Phase 2 meeting request to the FDA in Q4 2025 for IPF chronic cough program.
• Complete enrollment and data availability for the Phase 1 TIDAL study in Q4 2025.
• Initiate comprehensive Phase 3 program for chronic cough in IPF in H1 2026.
• Initiate Phase 2b RCC study in H1 2026.

Key Dates

Recommendation

The company demonstrates strong operational execution with significant progress in its clinical pipeline, particularly the advancement of Haduvio into Phase 3 for IPF chronic cough and Phase 2b for RCC, addressing large unmet medical needs with no approved therapies. Financially, the company has substantially strengthened its balance sheet with $194.9 million in cash and an extended runway into 2028, while also reducing its net loss. These factors, combined with positive clinical data and a clear strategic path, suggest a favorable outlook for long-term growth and potential market penetration, making it an attractive investment for growth-oriented portfolios despite the inherent risks of clinical-stage biopharmaceuticals.

Keywords

Trevi Therapeutics, TRVI, Haduvio, nalbuphine ER, chronic cough, idiopathic pulmonary fibrosis, IPF, refractory chronic cough, RCC, biopharmaceutical, clinical-stage, Phase 3, Phase 2b, FDA, drug development, Q3 2025 earnings, financial results